BIAF vs. ONMD, LUNA, OCG, EHGO, HTCR, JOB, WHLM, VCIG, LTRPA, and CJMB
Should you be buying bioAffinity Technologies stock or one of its competitors? The main competitors of bioAffinity Technologies include OneMedNet (ONMD), Luna Innovations (LUNA), Oriental Culture (OCG), Eshallgo (EHGO), HeartCore Enterprises (HTCR), GEE Group (JOB), Wilhelmina International (WHLM), VCI Global (VCIG), Liberty TripAdvisor (LTRPA), and Callan Jmb (CJMB). These companies are all part of the "business services" industry.
bioAffinity Technologies vs.
bioAffinity Technologies (NASDAQ:BIAF) and OneMedNet (NASDAQ:ONMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation.
In the previous week, OneMedNet had 2 more articles in the media than bioAffinity Technologies. MarketBeat recorded 4 mentions for OneMedNet and 2 mentions for bioAffinity Technologies. OneMedNet's average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.59 indicating that OneMedNet is being referred to more favorably in the news media.
bioAffinity Technologies currently has a consensus price target of $6.00, indicating a potential upside of 1,592.52%. Given bioAffinity Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe bioAffinity Technologies is more favorable than OneMedNet.
bioAffinity Technologies has higher revenue and earnings than OneMedNet.
bioAffinity Technologies has a net margin of -91.22% compared to OneMedNet's net margin of -1,093.61%. OneMedNet's return on equity of 0.00% beat bioAffinity Technologies' return on equity.
bioAffinity Technologies has a beta of 3.13, suggesting that its stock price is 213% more volatile than the S&P 500. Comparatively, OneMedNet has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
bioAffinity Technologies received 1 more outperform votes than OneMedNet when rated by MarketBeat users.
1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 0.9% of OneMedNet shares are owned by institutional investors. 35.1% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 44.7% of OneMedNet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
bioAffinity Technologies beats OneMedNet on 10 of the 15 factors compared between the two stocks.
Get bioAffinity Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIAF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bioAffinity Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:BIAF) was last updated on 3/12/2025 by MarketBeat.com Staff
